Related Experiment Video

Updated: Aug 7, 2026

Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads
07:59

Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads

Published on: July 21, 2017

Influence of HMG-CoA-reductase inhibitors on the body fat status

R A Bucek1, M Reiter, S Wirth

  • 1University Clinic of Internal Medicine 2, Department of Angiology, Vienna Medical School, Austria. robert.bucek@meduniwien.ac.at

VASA. Zeitschrift Fur Gefasskrankheiten
|June 27, 2006
PubMed

Insights

Simvastatin, a statin, may increase body fat percentage over time, unlike atorvastatin. This finding suggests statins do not improve body fat status, a key factor in cardiovascular risk prevention.

Area of Science:

  • Cardiovascular Pharmacology
  • Metabolic Health
  • Lipid Management

Background:

  • HMG-CoA reductase inhibitors (statins) effectively lower plasma lipids.
  • Limited data exists on statins' impact on body fat composition.
  • Understanding body fat changes is crucial for cardiovascular risk reduction.

Purpose of the Study:

  • To investigate the effects of atorvastatin and simvastatin on body fat status.
  • To compare body fat changes in hyperlipidemic patients treated with different statins versus a control group.
  • To assess the influence of statin therapy on cardiovascular risk factors beyond lipid levels.

Main Methods:

  • Retrospective analysis of a prospective randomized controlled trial.
  • Inclusion of normolipidemic controls and hyperlipidemic patients randomized to atorvastatin or simvastatin.
  • Assessment of relative body fat, waist circumference, BMI, cholesterol, LDL, and triglycerides at baseline, 6 weeks, and 6 months.

Main Results:

  • Body fat remained unchanged in control and atorvastatin groups (p > 0.05).
  • Simvastatin treatment showed a significant increase in relative body fat (+4.2%) between 6 weeks and 6 months (p = 0.013).
  • No significant changes in BMI or waist circumference were observed in any group.

Conclusions:

  • Long-term statin use, specifically simvastatin, may not positively influence body fat status.
  • Statins may not contribute to cardiovascular risk prevention through body fat modulation.
  • Further research is needed to elucidate the differential effects of statins on body composition.
Abstract

More Related Videos

Assessing Whole-Body Lipid-Handling Capacity in Mice07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...